Proficio Capital Partners LLC Takes $5.81 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Proficio Capital Partners LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 74,737 shares of the medical device company's stock, valued at approximately $5,812,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Whale Capital LLP increased its stake in DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after purchasing an additional 113,000 shares in the last quarter. Motley Fool Asset Management LLC grew its holdings in DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock valued at $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC purchased a new position in shares of DexCom in the fourth quarter valued at $3,334,000. Congress Asset Management Co. raised its stake in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after buying an additional 222,548 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. Company insiders own 0.30% of the company's stock.

Remove Ads

DexCom Trading Up 2.4 %

Shares of DXCM traded up $1.77 during trading hours on Thursday, hitting $75.15. The stock had a trading volume of 2,491,697 shares, compared to its average volume of 3,888,783. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a market cap of $29.37 billion, a P/E ratio of 52.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company's fifty day simple moving average is $83.51 and its 200 day simple moving average is $76.93.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.